


This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Original) Compounds of the formula I



in which

$R^1, R^2$ , independently of one another, denotes H, A, Hal,  $(CH_2)_n$ Het,  $(CH_2)_n$ Ar, cycloalkyl having 3 to 7 C atoms,  $CF_3$ ,  $NO_2$ , CN,  $C(NH)NOH$  or  $OCF_3$ , OH, OA,  $NH_2$ , NHA,  $NA_2$ ,

Q denotes  $NR^3R^4$  or Het,


$R^3, R^4$  denotes H,  $(CH_2)_n$ Het,  $(CH_2)_n$ Ar, A, cycloalkyl having 3 to 7 C atoms or  $CF_3$ ,

$R^5$  denotes A, Ar or Het

A denotes straight-chain or branched alkyl or alkoxy having 1 to 10 C atoms, alkenyl or alkoxyalkyl having 2 to 10 C atoms,

Het denotes an organic heteroatom-containing radical, in particular a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic or linear or branched organic radical containing one or more hetero atoms which is unsubstituted or mono- or polysubstituted by A, cycloalkyl having 3 to 7 C atoms, OH, OA,  $NH_2$ , NAH,  $NA_2$ ,  $NO_2$ , CN and/or Hal,

Ar denotes an aromatic organic radical, in particular a phenyl radical which is unsubstituted or mono- or polysubstituted by A and/or Hal,  $OR^5$ ,  $OOCR^5$ ,  $COOR^5$ ,  $CON(R^5)_2$ , CN,  $NO_2$ ,  $NH_2$ ,  $NHCOR^5$ ,  $CF_3$ ,  $SO_2CH_3$  or a ring-containing group  $-OCH_2O-$ ,



n denotes 0, 1, 2, 3, 4 or 5

m denotes 1, 2 or 3


Hal denotes F, Cl, Br or I

and  
denotes N or CH,

and salts and solvates, enantiomers, racemates thereof and other mixtures of the enantiomers, in particular physiologically tolerated salts and solvates thereof.

2. (Original) Compounds of the formula I according to Claim 1, in which R<sup>1</sup> denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro-, dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl.
3. (Currently Amended) Compounds of the formula I according to Claim 1 ~~one or more of the preceding claims~~, in which R<sup>3</sup> denotes H.
4. (Currently Amended) Compounds of the formula I according to Claim 1 ~~one or more of the preceding claims~~, in which R<sup>4</sup> denotes H.
5. (Currently Amended) Compounds of the formula I according to Claim 1 ~~one or more of the preceding claims~~, in which R<sup>2</sup> denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinoliny, isoquinoliny, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl.
6. (Currently Amended) Compounds of the formula I according to Claim 1 ~~one or more of the preceding claims~~, in which X has the meaning N.


7. (Original) Compounds of the formula IA:



in which


$R^1$ ,  $R^2$ ,  $R^5$  and X have the meanings indicated in Claim 1.

8. (Original) Process for the preparation of compounds of the formula IA



in which  $R^1$ ,  $R^2$ ,  $R^5$  and X have the meaning indicated in Claim 1

and salts and solvates thereof, which is characterised in that a compound of the formula II




or acid-addition salts thereof

in which

$R^1$ ,  $R^2$  and X have the meanings indicated in Claim 1,

is reacted with a compound of the formula III



III

in which

R<sup>5</sup> has the meaning indicated in Claim 1,

and/or in that a basic compound of the formula IA is converted into one of its salts by treatment with an acid.

9. (Currently Amended) Compounds of the formula I according to Claim 1 ~~one or more of Claims 1 to 6~~ and physiologically acceptable salts and solvates thereof as medicaments.
10. (Currently Amended) Use of the compounds of the formula I according to Claim 1 ~~one or more of Claims 1 to 6~~, and salts and solvates thereof, for the preparation of a medicament for the treatment and prophylaxis of diseases which can be influenced by the binding of the compounds of the formula I to 5-HT receptors.
11. (Currently Amended) Use of compounds of the formula I according to Claim 1 ~~one or more of Claims 1 to 6~~ and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament having a 5-HT receptor-antagonistic action.
12. (Currently Amended) Use of compounds of the formula I according to Claim 1 ~~one or more of Claims 1 to 6~~ and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament having a 5-HT<sub>2A</sub> receptor-antagonistic action.
13. (Currently Amended) Pharmaceutical composition characterised by a content of at least one compound of the formula I according to Claim 1 ~~one or more of Claims 1 to 6~~ and/or one of its physiologically acceptable salts and/or one of its solvates.
14. (Original) Process for the preparation of pharmaceutical compositions, characterised in that a compound of the formula I according to Claim 1 and/or one of its physiologically acceptable salts and/or one of its solvates is converted into a suitable dosage form together with at least one solid, liquid or

semi-liquid excipient or adjuvant.

15. (Currently Amended) Use of compounds of the formula according to Claim 1 ~~one or more of Claims 1 to 6~~ and/or physiologically acceptable salts or solvates thereof for the preparation of a medicament for the prophylaxis and/or treatment of psychoses, neurological disorders, amyotrophic lateral sclerosis, eating disorders, such as bulimia, anorexia nervosa, of premenstrual syndrome and/or for positively influencing obsessive-compulsive disorder (OCD).

16. (Original) Compounds of the formula I in which Het denotes one of the following radicals:

